Validation of multiplex ligation-dependent probe amplification for confirmation of array comparative genomic hybridization

Lawrence J. Jennings*, Min Yu, Carrie Fitzpatrick, Frederick A. Smith

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The American College of Medical Genetics recommends that each laboratory should confirm abnormal or ambiguous results detected by array comparative genomic hybridization (aCGH). At present, the gold standard method for aCGH confirmation is fluorescent in situ hybridization (FISH). However, FISH is not well suited for small tandem duplications or very small deletions that are detectable by oligonucleotide arrays. Therefore, we developed and validated multiplex ligation-dependent probe amplification (MLPA) for aCGH confirmation. The method performance validation showed linearity through the expected analytical measurement range (0.05 to 2 genome equivalents). The interassay normalized coefficient of variation averaged 3.7% across 12 control and target probes. This low imprecision allowed detection of 20% mosaicism with exceptional confidence (P<0.006). Comparison with a combined gold standard of phenotype, aCGH, karyotype, and/ or FISH showed 100% concordance for 218 samples using an X/Y chromosome-specific probe set (95% confidence interval, 98.3%-100.0%). Patient-specific probe sets also showed 100% concordance to the gold standard for 18 genomic targets. In conclusion, we have developed and validated an MLPA assay using a novel approach to accommodate the fact that positive controls would not be available at the time of testing. We initially validated the MLPA method using X/Y chromosome-specific probes and well-characterized samples and then validated new probe sets by comparision with reference populations. We have successfully incorporated aCGH confirmation using custom-designed MLPA into our normal workflow, and used it for confirmation of all abnormal or ambiguous results.

Original languageEnglish (US)
Pages (from-to)166-174
Number of pages9
JournalDiagnostic Molecular Pathology
Volume20
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Comparative Genomic Hybridization
Multiplex Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Y Chromosome
X Chromosome
Mosaicism
Workflow
Oligonucleotide Array Sequence Analysis
Karyotype
Genome
Confidence Intervals
Phenotype
Population

Keywords

  • Copy Number Variation
  • MLPA
  • aCGH
  • microarray
  • validation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

@article{24a95d8045ed49cba3910c9d22521ca7,
title = "Validation of multiplex ligation-dependent probe amplification for confirmation of array comparative genomic hybridization",
abstract = "The American College of Medical Genetics recommends that each laboratory should confirm abnormal or ambiguous results detected by array comparative genomic hybridization (aCGH). At present, the gold standard method for aCGH confirmation is fluorescent in situ hybridization (FISH). However, FISH is not well suited for small tandem duplications or very small deletions that are detectable by oligonucleotide arrays. Therefore, we developed and validated multiplex ligation-dependent probe amplification (MLPA) for aCGH confirmation. The method performance validation showed linearity through the expected analytical measurement range (0.05 to 2 genome equivalents). The interassay normalized coefficient of variation averaged 3.7{\%} across 12 control and target probes. This low imprecision allowed detection of 20{\%} mosaicism with exceptional confidence (P<0.006). Comparison with a combined gold standard of phenotype, aCGH, karyotype, and/ or FISH showed 100{\%} concordance for 218 samples using an X/Y chromosome-specific probe set (95{\%} confidence interval, 98.3{\%}-100.0{\%}). Patient-specific probe sets also showed 100{\%} concordance to the gold standard for 18 genomic targets. In conclusion, we have developed and validated an MLPA assay using a novel approach to accommodate the fact that positive controls would not be available at the time of testing. We initially validated the MLPA method using X/Y chromosome-specific probes and well-characterized samples and then validated new probe sets by comparision with reference populations. We have successfully incorporated aCGH confirmation using custom-designed MLPA into our normal workflow, and used it for confirmation of all abnormal or ambiguous results.",
keywords = "Copy Number Variation, MLPA, aCGH, microarray, validation",
author = "Jennings, {Lawrence J.} and Min Yu and Carrie Fitzpatrick and Smith, {Frederick A.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/PDM.0b013e31820b2517",
language = "English (US)",
volume = "20",
pages = "166--174",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Validation of multiplex ligation-dependent probe amplification for confirmation of array comparative genomic hybridization. / Jennings, Lawrence J.; Yu, Min; Fitzpatrick, Carrie; Smith, Frederick A.

In: Diagnostic Molecular Pathology, Vol. 20, No. 3, 01.09.2011, p. 166-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validation of multiplex ligation-dependent probe amplification for confirmation of array comparative genomic hybridization

AU - Jennings, Lawrence J.

AU - Yu, Min

AU - Fitzpatrick, Carrie

AU - Smith, Frederick A.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The American College of Medical Genetics recommends that each laboratory should confirm abnormal or ambiguous results detected by array comparative genomic hybridization (aCGH). At present, the gold standard method for aCGH confirmation is fluorescent in situ hybridization (FISH). However, FISH is not well suited for small tandem duplications or very small deletions that are detectable by oligonucleotide arrays. Therefore, we developed and validated multiplex ligation-dependent probe amplification (MLPA) for aCGH confirmation. The method performance validation showed linearity through the expected analytical measurement range (0.05 to 2 genome equivalents). The interassay normalized coefficient of variation averaged 3.7% across 12 control and target probes. This low imprecision allowed detection of 20% mosaicism with exceptional confidence (P<0.006). Comparison with a combined gold standard of phenotype, aCGH, karyotype, and/ or FISH showed 100% concordance for 218 samples using an X/Y chromosome-specific probe set (95% confidence interval, 98.3%-100.0%). Patient-specific probe sets also showed 100% concordance to the gold standard for 18 genomic targets. In conclusion, we have developed and validated an MLPA assay using a novel approach to accommodate the fact that positive controls would not be available at the time of testing. We initially validated the MLPA method using X/Y chromosome-specific probes and well-characterized samples and then validated new probe sets by comparision with reference populations. We have successfully incorporated aCGH confirmation using custom-designed MLPA into our normal workflow, and used it for confirmation of all abnormal or ambiguous results.

AB - The American College of Medical Genetics recommends that each laboratory should confirm abnormal or ambiguous results detected by array comparative genomic hybridization (aCGH). At present, the gold standard method for aCGH confirmation is fluorescent in situ hybridization (FISH). However, FISH is not well suited for small tandem duplications or very small deletions that are detectable by oligonucleotide arrays. Therefore, we developed and validated multiplex ligation-dependent probe amplification (MLPA) for aCGH confirmation. The method performance validation showed linearity through the expected analytical measurement range (0.05 to 2 genome equivalents). The interassay normalized coefficient of variation averaged 3.7% across 12 control and target probes. This low imprecision allowed detection of 20% mosaicism with exceptional confidence (P<0.006). Comparison with a combined gold standard of phenotype, aCGH, karyotype, and/ or FISH showed 100% concordance for 218 samples using an X/Y chromosome-specific probe set (95% confidence interval, 98.3%-100.0%). Patient-specific probe sets also showed 100% concordance to the gold standard for 18 genomic targets. In conclusion, we have developed and validated an MLPA assay using a novel approach to accommodate the fact that positive controls would not be available at the time of testing. We initially validated the MLPA method using X/Y chromosome-specific probes and well-characterized samples and then validated new probe sets by comparision with reference populations. We have successfully incorporated aCGH confirmation using custom-designed MLPA into our normal workflow, and used it for confirmation of all abnormal or ambiguous results.

KW - Copy Number Variation

KW - MLPA

KW - aCGH

KW - microarray

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=80052259071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052259071&partnerID=8YFLogxK

U2 - 10.1097/PDM.0b013e31820b2517

DO - 10.1097/PDM.0b013e31820b2517

M3 - Article

C2 - 21817904

AN - SCOPUS:80052259071

VL - 20

SP - 166

EP - 174

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 3

ER -